PT - JOURNAL ARTICLE AU - Ahava, MJ AU - Jarva, H AU - Jääskeläinen, AJ AU - Lappalainen, M AU - Vapalahti, O AU - Kurkela, S TI - Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland AID - 10.1101/2022.03.25.22272952 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.25.22272952 4099 - http://medrxiv.org/content/early/2022/03/30/2022.03.25.22272952.short 4100 - http://medrxiv.org/content/early/2022/03/30/2022.03.25.22272952.full AB - Objectives The aim of this study was to assess changes in exposure and prevalence of SARS-CoV-2 infection during the first months of emergence of Omicron variant in the Greater Helsinki area, Finland.Methods A prospective seroepidemiological survey of SARS-CoV-2 was conducted on 1,600 serum specimens sent to Helsinki University Hospital Laboratory (HUSLAB) for HIV serology between 15 November 2021 and 6 March 2022 (calendar weeks 46/2021 – 9/2022). For each calendar week, 100 serum specimens were randomly selected and analysed for SARS-CoV-2 IgG antibodies against nucleocapsid (N) and spike 1 (S1) protein with Abbott SARS-CoV-2 IgG (N protein) and SARS-CoV-2 IgG II Quant (S protein) tests, respectively.Results The prevalence of N antibodies increased from 5.2% (weeks 46-50/2021) to 28.2% (weeks 5-9/2022) during the study period. The proportion of seronegative samples as well as anti-N negative, anti-S1 positive samples decreased correspondingly from 11.6% to 3.8%, and 84.2% to 68.2%, respectively. Anti-N positive samples that were anti-S1 negative only began to appear as of week 2/2022.Conclusions A rapid increase in the N antibody prevalence was observed over the study period, suggesting a high transmission rate. A substantial proportion of COVID-19 cases remained undiagnosed during the emergence of Omicron variant in the Greater Helsinki Area, Finland.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by Helsinki University and Helsinki University Hospital, HUSLAB, Helsinki, Finland (TYH2021110, TYH2021343, Y780022023 and Y780022035).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee and institutional review board of Helsinki University Hospital gave ethical approval for this work. Research permit HUS/56/2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available upon reasonable request from the corresponding author.